(2,4-difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone

(2,4-difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone, often abbreviated as **DFP-MOP**, is a chemical compound with a complex structure. It's important for research primarily due to its **pharmacological activity** as a **potent and selective antagonist of the kappa opioid receptor**.

Here's a breakdown of its key features and significance:

* **Structure:** The molecule is a combination of different functional groups: a difluorophenyl ring, a piperidine ring, and a 1,2,4-oxadiazole ring attached to a 4-methylphenyl ring. This unique structure is crucial for its interaction with the kappa opioid receptor.
* **Kappa Opioid Receptor Antagonism:** DFP-MOP blocks the binding of endogenous opioid ligands (like dynorphin) and exogenous opioid drugs (like pentazocine) to the kappa opioid receptor. This antagonism has a significant impact on various biological processes.
* **Research Significance:**
* **Understanding Kappa Opioid Receptor Function:** DFP-MOP is a valuable tool for researchers studying the role of the kappa opioid receptor in various physiological and pathological processes. This receptor is implicated in pain perception, mood disorders, drug addiction, and immune function.
* **Developing Novel Therapies:** DFP-MOP's ability to block the kappa receptor opens up possibilities for developing new drugs to treat conditions like depression, anxiety, and chronic pain. Some research suggests that kappa receptor antagonists might have therapeutic potential in treating opioid addiction by reducing cravings and withdrawal symptoms.
* **Preclinical Studies:** DFP-MOP has been used extensively in preclinical studies to investigate the therapeutic potential of kappa receptor antagonism in various disease models.

**Important Notes:**

* **Not FDA Approved:** DFP-MOP is currently not approved for use in humans as a therapeutic agent.
* **Clinical Trials:** While research on DFP-MOP is promising, it's still in early stages, and more research, including clinical trials, is necessary to evaluate its safety and efficacy in humans.
* **Pharmacokinetics:** DFP-MOP's pharmacokinetic properties (absorption, distribution, metabolism, and excretion) are crucial for its therapeutic potential. Researchers are studying these aspects to optimize its use in future drug development.

In conclusion, (2,4-difluorophenyl)-[3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-yl]-1-piperidinyl]methanone (DFP-MOP) is a significant research compound due to its potent and selective antagonism of the kappa opioid receptor. Its potential therapeutic applications in treating various conditions, including pain, depression, and addiction, make it an active area of investigation.